Grant agreement number: (no. S-BMT-21-9 (LT08-2-LMT-K-01-041))
Aim of the project: By using in vitro and in vivo models, including patientderived xenografts, project aimed to evaluate the potential of AHR inhibition in PC therapy, assess the activities of AHR and ELAVL1 pathways in PC patients, to determine the subsets of patients who would benefit most from AHR inhibition, thereby enabling a more personalized approach in future PC therapy.
Source of funding: European Economic Area (EEA) (Iceland, Liechtenstein, Norway) Financial Mechanism 2014-2021